Skip to main content
. 2022 Jun 15;6:e2200147. doi: 10.1200/PO.22.00147

FIG A3.

FIG A3.

Signature expression predicts selinexor response in recurrent glioblastoma. (A) Survival analysis of the KING recurrent glioblastoma cohort stratified by three-gene signature GSVA scores. (B) Three-gene signature GSVA scores in the KING cohort in responders (teal) versus nonresponders (orange). GSVA, Gene Set Variation Analysis; HR, hazard ratio; PFS, progression-free survival; PH, proportional hazard; PR, partial response.